Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/PKN2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PKN2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PKN2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PKN2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/PKN2_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PKN2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PKN2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PKN2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PKN2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PKN2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PKN2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00009107 | Cervix | CC | cytokinesis | 37/2311 | 173/18723 | 5.40e-04 | 5.23e-03 | 37 |
GO:00450698 | Cervix | CC | regulation of viral genome replication | 21/2311 | 85/18723 | 1.27e-03 | 1.01e-02 | 21 |
GO:0032465 | Cervix | CC | regulation of cytokinesis | 22/2311 | 92/18723 | 1.55e-03 | 1.20e-02 | 22 |
GO:0016032 | Colorectum | AD | viral process | 168/3918 | 415/18723 | 4.67e-20 | 3.66e-17 | 168 |
GO:0019058 | Colorectum | AD | viral life cycle | 119/3918 | 317/18723 | 6.18e-12 | 8.23e-10 | 119 |
GO:0045216 | Colorectum | AD | cell-cell junction organization | 80/3918 | 200/18723 | 5.57e-10 | 4.58e-08 | 80 |
GO:0034329 | Colorectum | AD | cell junction assembly | 136/3918 | 420/18723 | 2.02e-08 | 1.15e-06 | 136 |
GO:0007043 | Colorectum | AD | cell-cell junction assembly | 57/3918 | 146/18723 | 4.18e-07 | 1.61e-05 | 57 |
GO:0048524 | Colorectum | AD | positive regulation of viral process | 31/3918 | 65/18723 | 1.33e-06 | 4.23e-05 | 31 |
GO:0019079 | Colorectum | AD | viral genome replication | 51/3918 | 131/18723 | 1.83e-06 | 5.51e-05 | 51 |
GO:0043297 | Colorectum | AD | apical junction assembly | 34/3918 | 78/18723 | 5.31e-06 | 1.37e-04 | 34 |
GO:0050792 | Colorectum | AD | regulation of viral process | 59/3918 | 164/18723 | 5.95e-06 | 1.52e-04 | 59 |
GO:0001667 | Colorectum | AD | ameboidal-type cell migration | 137/3918 | 475/18723 | 2.17e-05 | 4.33e-04 | 137 |
GO:0000910 | Colorectum | AD | cytokinesis | 59/3918 | 173/18723 | 3.74e-05 | 6.75e-04 | 59 |
GO:1903900 | Colorectum | AD | regulation of viral life cycle | 51/3918 | 148/18723 | 9.01e-05 | 1.38e-03 | 51 |
GO:0090132 | Colorectum | AD | epithelium migration | 105/3918 | 360/18723 | 1.18e-04 | 1.73e-03 | 105 |
GO:0010631 | Colorectum | AD | epithelial cell migration | 104/3918 | 357/18723 | 1.33e-04 | 1.90e-03 | 104 |
GO:0090130 | Colorectum | AD | tissue migration | 105/3918 | 365/18723 | 2.10e-04 | 2.77e-03 | 105 |
GO:0045069 | Colorectum | AD | regulation of viral genome replication | 32/3918 | 85/18723 | 2.97e-04 | 3.60e-03 | 32 |
GO:0045070 | Colorectum | AD | positive regulation of viral genome replication | 14/3918 | 30/18723 | 1.43e-03 | 1.22e-02 | 14 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PKN2 | SNV | Missense_Mutation | | c.1450N>A | p.Glu484Lys | p.E484K | Q16513 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
PKN2 | SNV | Missense_Mutation | rs200905692 | c.2900C>T | p.Ser967Leu | p.S967L | Q16513 | protein_coding | tolerated(0.07) | benign(0.003) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PKN2 | SNV | Missense_Mutation | | c.164A>C | p.Glu55Ala | p.E55A | Q16513 | protein_coding | tolerated(0.32) | probably_damaging(0.989) | TCGA-AR-A1AU-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
PKN2 | SNV | Missense_Mutation | | c.2692N>T | p.Arg898Trp | p.R898W | Q16513 | protein_coding | deleterious(0) | possibly_damaging(0.727) | TCGA-BH-A0DK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
PKN2 | SNV | Missense_Mutation | | c.2479G>A | p.Glu827Lys | p.E827K | Q16513 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PKN2 | SNV | Missense_Mutation | | c.2479N>C | p.Glu827Gln | p.E827Q | Q16513 | protein_coding | deleterious(0) | probably_damaging(0.932) | TCGA-D8-A1JD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PKN2 | SNV | Missense_Mutation | novel | c.2371N>A | p.Asp791Asn | p.D791N | Q16513 | protein_coding | deleterious(0.01) | probably_damaging(0.971) | TCGA-S3-AA17-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
PKN2 | insertion | Frame_Shift_Ins | novel | c.463_464insTCAAGACTAGCCTGGCCAAGATGGTGAAACC | p.Ala155ValfsTer57 | p.A155Vfs*57 | Q16513 | protein_coding | | | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PKN2 | insertion | Frame_Shift_Ins | novel | c.232_233insACATACAAAT | p.Ser78AsnfsTer17 | p.S78Nfs*17 | Q16513 | protein_coding | | | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PKN2 | insertion | Frame_Shift_Ins | novel | c.1148_1149insC | p.Leu384SerfsTer5 | p.L384Sfs*5 | Q16513 | protein_coding | | | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5586 | PKN2 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE | | PF-562271 | PF-00562271 | |
5586 | PKN2 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE | | ERLOTINIB | ERLOTINIB | |
5586 | PKN2 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE | | DOVITINIB | DOVITINIB | |
5586 | PKN2 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE | | BAY-613606 | CHEMBL541400 | |
5586 | PKN2 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE | inhibitor | 178101973 | | |
5586 | PKN2 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE | | ENTRECTINIB | ENTRECTINIB | |
5586 | PKN2 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE | | RG-1530 | RG-1530 | |
5586 | PKN2 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE | | ILORASERTIB | ILORASERTIB | |
5586 | PKN2 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE | | 681640 | CHEMBL379975 | |
5586 | PKN2 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE | | DASATINIB | DASATINIB | |